Harnessing Innate and Adaptive Immune Responses to Cure Disease
Building upon the long-standing observation of tumor regression in the setting of bacterial infection, we have developed a unique and patented approach designed to exploit bacteria’s natural ability to fully engage the human immune system and cure disease. Our novel insights have enabled us to create proprietary, attenuated and killed non-pathogenic gram-negative bacteria that have demonstrated broad anti-tumor and anti-viral activity in pre-clinical models to date.
Latest Press Release
Indaptus Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
September 6, 2022
New York (September 6, 2022) Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer will present a corporate overview at the 24th Annual H.C. Wainwright Global Investment Conference. The conference is being held on September 12 – 14 at the Lotte New York Palace Hotel. read more →